VMS - Vaginal Microbiome Screening Commercialisation and scale up of a Vaginal Microbiome Screening service with a menstrual tampon collection device and a digital layer to provide diagnosis, disease risk evaluation and aftercare.
- Coordinator
- Tamponeni Inovatsii Ood, Bulgaria
- Runs
- 1 July 2023 to 30 June 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.8m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190192897
What the project is doing
In the project's own words, from its summary on CORDIS.
VMS is a home-based gynaecological test kit, using a menstrual tampon for sample collection. VMS will improve the accuracy and convenience with which STI, vaginal infections and HPV screening is undertaken. Daye has patented the proprietary protocol for DNA extraction from a tampon for PCR analysis, testing for 16 different factors at a time. VMS can be used to detect vaginal dysbiosis, HPV and STIs, like chlamydia, gonorrhea and trichomoniasis.
Vaginal microbiome screening with VMS will unlock invaluable insights into our customers’ vaginal health. There’s a direct correlation between vaginal microbiome health and the likelihood of contracting an STI, developing a gynecological cancer, experiencing fertility and pregnancy challenges, as well as susceptibility to recurrent vaginal and urethral infections. Post screen, VMS will offer comprehensive aftercare, including prescriptions, doctor consultations, booking in-person visits, and vaginal microbiome enhancement plan with probiotics
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Tamponeni Inovatsii Ood | Sofia | Bulgaria | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI